These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 24398380)
1. Targeting the Warburg Effect in cancer; relationships for 2-arylpyridazinones as inhibitors of the key glycolytic enzyme 6-phosphofructo-2-kinase/2,6-bisphosphatase 3 (PFKFB3). Brooke DG; van Dam EM; Watts CK; Khoury A; Dziadek MA; Brooks H; Graham LJ; Flanagan JU; Denny WA Bioorg Med Chem; 2014 Feb; 22(3):1029-39. PubMed ID: 24398380 [TBL] [Abstract][Full Text] [Related]
2. PFKFB3 inhibitors as potential anticancer agents: Mechanisms of action, current developments, and structure-activity relationships. Wang Y; Qu C; Liu T; Wang C Eur J Med Chem; 2020 Oct; 203():112612. PubMed ID: 32679452 [TBL] [Abstract][Full Text] [Related]
3. Structure-based design of small-molecule ligands of phosphofructokinase-2 activating or inhibiting glycolysis. Pyrkov TV; Sevostyanova IA; Schmalhausen EV; Shkoporov AN; Vinnik AA; Muronetz VI; Severin FF; Fedichev PO ChemMedChem; 2013 Aug; 8(8):1322-9. PubMed ID: 23813838 [TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer. Bando H; Atsumi T; Nishio T; Niwa H; Mishima S; Shimizu C; Yoshioka N; Bucala R; Koike T Clin Cancer Res; 2005 Aug; 11(16):5784-92. PubMed ID: 16115917 [TBL] [Abstract][Full Text] [Related]
12. Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. Clem BF; O'Neal J; Tapolsky G; Clem AL; Imbert-Fernandez Y; Kerr DA; Klarer AC; Redman R; Miller DM; Trent JO; Telang S; Chesney J Mol Cancer Ther; 2013 Aug; 12(8):1461-70. PubMed ID: 23674815 [TBL] [Abstract][Full Text] [Related]
13. A High-Throughput Screening Triage Workflow to Authenticate a Novel Series of PFKFB3 Inhibitors. St-Gallay SA; Bennett N; Critchlow SE; Curtis N; Davies G; Debreczeni J; Evans N; Hardern I; Holdgate G; Jones NP; Leach L; Maman S; McLoughlin S; Preston M; Rigoreau L; Thomas A; Turnbull AP; Walker G; Walsh J; Ward RA; Wheatley E; Winter-Holt J SLAS Discov; 2018 Jan; 23(1):11-22. PubMed ID: 28945981 [TBL] [Abstract][Full Text] [Related]
14. Discover potential inhibitors for PFKFB3 using 3D-QSAR, virtual screening, molecular docking and molecular dynamics simulation. Bao Y; Zhou L; Dai D; Zhu X; Hu Y; Qiu Y J Recept Signal Transduct Res; 2018; 38(5-6):413-431. PubMed ID: 30822195 [TBL] [Abstract][Full Text] [Related]
15. PFKFB3 gene silencing decreases glycolysis, induces cell-cycle delay and inhibits anchorage-independent growth in HeLa cells. Calvo MN; Bartrons R; Castaño E; Perales JC; Navarro-Sabaté A; Manzano A FEBS Lett; 2006 May; 580(13):3308-14. PubMed ID: 16698023 [TBL] [Abstract][Full Text] [Related]
16. 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 and 4: A pair of valves for fine-tuning of glucose metabolism in human cancer. Yi M; Ban Y; Tan Y; Xiong W; Li G; Xiang B Mol Metab; 2019 Feb; 20():1-13. PubMed ID: 30553771 [TBL] [Abstract][Full Text] [Related]
17. Small molecule 3PO inhibits glycolysis but does not bind to 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3). Emini Veseli B; Perrotta P; Van Wielendaele P; Lambeir AM; Abdali A; Bellosta S; Monaco G; Bultynck G; Martinet W; De Meyer GRY FEBS Lett; 2020 Sep; 594(18):3067-3075. PubMed ID: 32620030 [TBL] [Abstract][Full Text] [Related]
18. Targeting the sugar metabolism of tumors with a first-in-class 6-phosphofructo-2-kinase (PFKFB4) inhibitor. Chesney J; Clark J; Lanceta L; Trent JO; Telang S Oncotarget; 2015 Jul; 6(20):18001-11. PubMed ID: 26221874 [TBL] [Abstract][Full Text] [Related]
19. Structure-based development of small molecule PFKFB3 inhibitors: a framework for potential cancer therapeutic agents targeting the Warburg effect. Seo M; Kim JD; Neau D; Sehgal I; Lee YH PLoS One; 2011; 6(9):e24179. PubMed ID: 21957443 [TBL] [Abstract][Full Text] [Related]